Comparison of nucleostemin gene expression in CD133+ and CD133− cell population in colon cancer cell line HT29

Zia-Jahromi, Noosha; Hejazi, Seyed Hossein; Panjepour, Mojtaba; Parivar, Kazem; Gharagozloo, Marjan

doi:10.4103/0973-1482.131375

Cited by 2 publications

(1 citation statement)

References 28 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GNL3 was initially named nucleostemin (NS) ( 17 ). GNL3 was subsequently shown to play significant roles in regulating cell proliferation and the cell cycle in various human cancers, such as gastric cancer, colorectal cancer, liver cancer and other malignancies ( 19 , 20 ). Furthermore, GNL3 also plays a crucial role in many other physiological and pathological processes, such as the resistance to apoptosis and cellular aging, cellular self-renewal, the maintenance of stemness, the inhibition of differentiation, ribosome biogenesis, the maintenance of genome stability and telomere integrity, radioresistance, the maintenance of tumor-initiating cells, and the induction of pluripotent stem cells ( 21 – 27 ).…”

Section: Introductionmentioning

confidence: 99%

Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

Tang

Zha

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

G protein nucleolar 3 (GNL3), a nucleolar GTP-binding protein, is highly expressed in progenitor cells, stem cells, and various types of cancer cells. Therefore, it is considered to have an important role in cancer pathogenesis. GNL3 has been reported to play crucial roles in cell proliferation, cell cycle regulation, inhibition of differentiation, ribosome biogenesis, and the maintenance of stemness, genome stability and telomere integrity. Furthermore, GNL3 has recently been shown to be involved in cancer invasion and metastasis. However, the biological significance of GNL3 in the invasion and metastasis of colon cancer remains unclear. This study was performed to address this gap in knowledge. GNL3 expression was upregulated in colon cancer tissue specimens and correlated with tumor differentiation, invasion and metastasis. GNL3 overexpression promoted cell proliferation, invasion, migration and the epithelial-mesenchymal transition (EMT) in colon cancer cells. Moreover, inhibition of the EMT and the Wnt/β-catenin signaling pathway induced by GNL3 knockdown was partially reversed by lithium chloride (LiCl). Based on these data, GNL3 promotes the EMT in colon cancer by activating the Wnt/β-catenin signaling pathway. In summary, GNL3 is upregulated in colon cancer and plays an important role in tumor growth, invasion and metastasis. Strategies targeting GNL3 are potential treatments for colon cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

Tang

Zha

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

show abstract

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a “ligand”. Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery.

show abstract

Comparison of nucleostemin gene expression in CD133+ and CD133− cell population in colon cancer cell line HT29

Abstract: It is concluded that nucleostemin expression could not be specific in a certain type of cells in colon cancer cell line HT29 and controlling strategies in colon cancer must not be focused on one certain type of colon cancer cells as main expressing nucleostemin gene.

Cited by 2 publications

References 28 publications

Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Contact Info

Product

Resources

About